Elizabeth M. Simzer

Elizabeth M. Simzer

Auto-generated profile, based on publicly available information

Elizabeth M. Simzer

Institute for Neuroscience and Cardiovascular Research, The University of Edinburgh, UK

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2024 in Acta Neuropathologica
Verified
Journal Article
Open access
PDF file
LTLewis W. Taylor
Lewis W. Taylor
ESElizabeth M. Simzer
Elizabeth M. Simzer
CPClaire Pimblett
Claire Pimblett
OLOscar T. T. Lacey-Solymar
Oscar T. T. Lacey-Solymar
RMRobert I. McGeachan
Robert I. McGeachan
CDClaire S. Durrant
Claire S. Durrant
Tau hyperphosphorylation and aggregation is a common feature of many dementia-causing neurodegenerative diseases. Tau can be phosphorylated at up to 85 different sites, and there is increasing interest in whether tau phosphorylation at specific epitopes, by specific kinases, plays an important role in disease progression. The AMP-activated protein kinase (AMPK)-related enzyme NUAK1 has been identified as a potential mediator of tau pathology, whereby NUAK1-mediated phosphorylation of tau at Ser356 prevents the degradation of tau by the proteasome, further exacerbating tau hyperphosphorylation and accumulation. This study provides a detailed characterisation of the association of p-tau Ser356 with progression of Alzheimer’s disease pathology, identifying a Braak stage-dependent increase in p-tau Ser356 protein levels and an almost ubiquitous presence in neurofibrillary tangles. We also demonstrate, using sub-diffraction-limit resolution array tomography imaging, that p-tau Ser356 co-localises with synapses in AD postmortem brain tissue, increasing evidence that this form of tau may play important roles in AD progression. To assess the potential impacts of pharmacological NUAK inhibition in an ex vivo system that retains multiple cell types and brain-relevant neuronal architecture, we treated postnatal mouse organotypic brain slice cultures from wildtype or APP/PS1 littermates with the commercially available NUAK1/2 inhibitor WZ4003. Whilst there were no genotype-specific effects, we found that WZ4003 results in a culture-phase-dependent loss of total tau and p-tau Ser356, which corresponds with a reduction in neuronal and synaptic proteins. By contrast, application of WZ4003 to live human brain slice cultures results in a specific lowering of p-tau Ser356, alongside increased neuronal tubulin protein. This work identifies differential responses of postnatal mouse organotypic brain slice cultures and adult human brain slice cultures to NUAK1 inhibition that will be important to consider in future work developing tau-targeting therapeutics for human disease.

20 September 2022 in medRxiv
Verified
Preprint
Open access
PDF file
RMRobert I McGeachan
Robert I McGeachan
LKLois Keavey
Lois Keavey
JRJamie L Rose
Jamie L Rose
ESElizabeth M Simzer
Elizabeth M Simzer
YCYa Yin Chang
Ya Yin Chang
TSTara L Spires-Jones
Tara L Spires-Jones
In the neurodegenerative disease Progressive Supranuclear Palsy (PSP), tau pathology progresses through the brain in a stereotypical spatiotemporal pattern, and where tau pathology appears, synapses are lost. We tested the hypothesis that tau pathology spreads between brain regions in PSP by moving from pre- to post-synapses. Sub-diffraction-limit microscopy of human post-mortem brain samples revealed that oligomeric tau is present in synaptic pairs in PSP, with an 80-fold increased chance of post-synapses containing tau when they oppose a tau-containing pre-synapse. In living human brain slice cultures, PSP-derived oligomeric tau was taken up by post-synapses. Synaptic engulfment by astrocytes was observed in both post-mortem brain and human brain slice cultures challenged with PSP-derived tau. These data indicate that tau pathology spreads via synapses in PSP and that astrocytes contribute to synapse loss. Targeting synaptic tau and astrocyte-mediated phagocytosis of synapses are promising targets for attenuating synaptic loss and pathology propagation in PSP.

2 May 2023 in Brain Communications
Verified
Journal Article
Open access
PDF file
ESElizabeth Simzer
Elizabeth Simzer
Welcome to Volume 5, Issue 3 of Brain Communications. In this editorial, I want to highlight a session from the third annual Brain Conference held on 16 March 2023. But first, we would like to congratulate our early career researcher paper prize1 winner George Thomas, who gave a fascinating presentation on his winning paper ‘Top-down and bottom-up connectivity changes in Parkinson’s disease visual hallucinators’.2 George stood out from the many competitive papers for his cutting-edge, robust research and contribution to promoting open access science through shared code and group-level data. Congratulations George! Keep an eye out for excellent papers by deserving early career researchers in Brain Communications this year, as we will be rerunning the prize with a call for nominations in January 2024.


11 June 2026 in Brain and Neuroscience Advances
Verified
Journal Article
Open access
ESElizabeth M. Simzer
Elizabeth M. Simzer
JEJamie A. Elliott
Jamie A. Elliott
SMSoraya Meftah
Soraya Meftah
SSSowmya Sekizar
Sowmya Sekizar
LYLauren F. P. Young
Lauren F. P. Young
JCJames H. Catterson
James H. Catterson
On 24–25 February 2026, Alzheimer’s Research UK held its annual research conference at Manchester Central Convention Complex and online. The meeting brought together over 700 researchers spanning molecular biology, data science, clinical trials, prevention, and patient engagement. Over 2 days of plenaries, parallel sessions, and discussions, a clear message emerged: the field of dementia research is entering a new, more hopeful era. This report summarises a meeting that highlighted how dementia research is moving beyond the search for a single solution and instead embracing a multidimensional, collaborative framework for precision care.

29 August 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
LTLewis W. Taylor
Lewis W. Taylor
ESElizabeth M. Simzer
Elizabeth M. Simzer
CPClaire Pimblett
Claire Pimblett
OLOscar T.T. Lacey-Solymar
Oscar T.T. Lacey-Solymar
RMRobert I. McGeachan
Robert I. McGeachan
CDClaire S. Durrant
Claire S. Durrant
Tau hyperphosphorylation and aggregation is a common feature of many dementia-causing neurodegenerative diseases. Tau can be phosphorylated at up to 85 different sites, and there is increasing interest in whether tau phosphorylation at specific epitopes, by specific kinases, plays an important role in disease progression. The AMP-activated protein kinase (AMPK) related enzyme NUAK1 been identified as a potential mediator of tau pathology, whereby NUAK1-mediated phosphorylation of tau at Ser356 prevents the degradation of tau by the proteasome, further exacerbating tau hyperphosphorylation and accumulation. This study provides a detailed characterisation of the association of p-tau Ser356 with progression of Alzheimer’s disease pathology, identifying a Braak stage-dependent increase in p-tau Ser356 protein levels and an almost ubiquitous presence in neurofibrillary tangles. We also demonstrate, using sub-diffraction-limit resolution array tomography imaging, that p-tau Ser356 co-localises with synapses in AD post-mortem brain tissue, increasing evidence that this form of tau may play important roles in AD progression. To assess the potential impacts of pharmacological NUAK inhibition in an ex vivo system that retains multiple cell types and brain-relevant neuronal architecture, we treated postnatal mouse organotypic brain slice cultures from wildtype or APP/PS1 littermates with the commercially available NUAK1/2 inhibitor WZ4003. Whilst there were no genotype specific effects, we found that WZ4003 results in a culture-phase dependent loss of total tau and p-tau Ser356, which corresponds with a reduction in neuronal and synaptic proteins. By contrast, application of WZ4003 to live human brain slice cultures results in a specific lowering of p-tau Ser356, alongside increased neuronal tubulin protein. This work identifies differential responses of postnatal mouse organotypic brain slice cultures and adult human brain slice cultures to NUAK1 inhibition that will be important to consider in future work developing tau-targeting therapeutics for human disease.